https://keshavmed.com/news/eha-adding-pirtobrutinib-to-venetoclax-rituximab-ups-pfs-in-chronic-lymphocytic-leukemia-ar/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-th/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/eha-adding-pirtobrutinib-to-venetoclax-rituximab-ups-pfs-in-chronic-lymphocytic-leukemia-ru/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-vi/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/eha-adding-pirtobrutinib-to-venetoclax-rituximab-ups-pfs-in-chronic-lymphocytic-leukemia-id/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/eha-adding-pirtobrutinib-to-venetoclax-rituximab-ups-pfs-in-chronic-lymphocytic-leukemia-th/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/eha-adding-pirtobrutinib-to-venetoclax-rituximab-ups-pfs-in-chronic-lymphocytic-leukemia-vi/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/eha-adding-pirtobrutinib-to-venetoclax-rituximab-ups-pfs-in-chronic-lymphocytic-leukemia-ms/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-zh-tw/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-fr/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-de/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-ja/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-pt/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-es/ 2026-07-11T06:35:28+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-th/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-vi/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-ms/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-zh-tw/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/hikma-acquires-novugens-fda-approved-anda-for-trametinib-hkmp-gurufocus-ms/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-fr/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-de/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-zh-tw/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-ja/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-fr/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-pt/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-de/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-es/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-ja/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-pt/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-es/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-ar/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-ru/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/trametinib-may-be-effective-option-for-relapsed-refractory-jmml-hematology-advisor-id/ 2026-07-11T06:35:27+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-zh-tw/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-fr/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-de/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-ja/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-pt/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-es/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-ar/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-ru/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-id/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-ar/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-th/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-ru/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-vi/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-id/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-pediatric-patients-with-braf-v600e-mutated-low-grade-glioma-onclive-ms/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-th/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-vi/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-zh-tw/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-in-low-grade-glioma-with-braf-v600e-mutation-cancernetwork-ms/ 2026-07-11T06:35:26+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-de/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-es/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-ja/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-ar/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-pt/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-ru/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-es/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-id/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-ar/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-ru/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-id/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-th/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-vi/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-ms/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-zh-tw/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-fr/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-de/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-ja/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/novartis-gets-cdsco-panel-nod-to-market-anticancer-drug-trametinib-and-dabrafenib-for-additional-medical-dialogues-fr/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-pt/ 2026-07-11T06:35:25+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-id/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-th/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-vi/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-ms/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-th/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-vi/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-zh-tw/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/eric-j-sherman-md-examines-trametinib-plus-paclitaxel-in-anaplastic-thyroid-cancer-cancernetwork-ms/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-fr/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-de/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-zh-tw/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-ja/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-fr/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-pt/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-de/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-ja/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-pt/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-es/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-ar/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-dabrafenib-plus-trametinib-for-braf-v600e-tumor-agnostic-indication-cancernetwork-ru/ 2026-07-11T06:35:24+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-ms/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-zh-tw/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-fr/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-de/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-ja/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-pt/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-es/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-ar/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-ru/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-es/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-id/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-ar/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-th/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-ru/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-vi/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-id/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/dabrafenib-plus-trametinib-could-be-new-standard-in-pediatric-low-grade-glioma-cancer-therapy-advisor-ms/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-th/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-approves-dabrafenib-plus-trametinib-for-unresectable-metastatic-solid-tumors-with-braf-v600e-mutation-pharmacy-times-vi/ 2026-07-11T06:35:23+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-fr/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-pt/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-de/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-es/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-ja/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-ar/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-pt/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-es/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-ar/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-ru/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-id/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-th/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-vi/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-ms/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-zh-tw/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-fr/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-de/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approvals-of-augtyro-repotrectinib-for-ntrk-gene-fusion-positive-solid-tumors-and-krazati-adagrasib-for-kras-g12c-mutated-colorectal-cancer-zh-tw/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-ja/ 2026-07-11T06:35:22+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-ru/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-id/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-th/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-ru/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-vi/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-id/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-ms/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-th/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-vi/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-zh-tw/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-retevmo-selpercatinib-for-advanced-or-metastatic-ret-fusion-positive-thyroid-cancer-ms/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-fr/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-de/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-zh-tw/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-fr/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-de/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-ja/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-pt/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-es/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-ogsiveo-nirogacestat-for-adult-patients-with-progressing-desmoid-tumors-who-require-systemic-treatment-ar/ 2026-07-11T06:35:21+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-vi/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-ms/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-zh-tw/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-fr/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-de/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-ja/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-pt/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-es/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-ja/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-ar/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-pt/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-ru/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-es/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-id/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-ar/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-th/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-ru/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-lynparza-olaparib-with-abiraterone-and-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer-vi/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-id/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-augtyro-repotrectinib-for-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-th/ 2026-07-11T06:35:20+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-zh-tw/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-fr/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-fr/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-fr/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-de/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-lorviqua-lorlatinib-date-of-authorisation-06-05-2019-revision-17-status-authorised-de/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-ja/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-de/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-pt/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-es/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-ar/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-ru/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-id/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/fda-d-i-s-c-o-burst-edition-fda-approval-of-tafinlar-dabrafenib-with-mekinist-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation-th/ 2026-07-11T06:35:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-retsevmo-selpercatinib-date-of-authorisation-11-02-2021-revision-21-status-authorised-zh-tw/ 2026-07-11T06:35:19+00:00